Experimental studies on the role of antibody fragments in cancer radio- immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy

International Journal of Cancer

Volumn 77, Issue 5, 1998, Pages 787-795

  Behr, Thomas M ^a   Memtsoudis, Stavros ^a   Sharkey, Robert M ^b   Blumenthal, Rosalyn D ^b   Dunn, Robert M ^b   Gratz, Stefan ^a   Wieland, Eberhard ^a   Nebendahl, Klaus ^a   Schmidberger, Heinz ^a   Goldenberg, David M ^b   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; DEXTRO LYSINE; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IODINE 131;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER THERAPY; CARCINOMA CELL; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031873327     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980831)77:5<787::AID-IJC19>3.0.CO;2-Z     Document Type: Article

References (52)

1. AMDUR, R.J. and BEDFORD, J.S., Dose-rate effects between 0.3 and 30 Gy/h in a normal and a malignant human cell line. Int. J. Radiat. Oncol. Biol. Phys., 30, 83-90 (1994).
2. BAXTER, L.T., YUAN, F. and JAIN, R.K., Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res., 52, 5838-5844 (1992).
3. BEHR, T.M., BECKER, W.S., SHARKEY, R.M., JUWEID, M.E., DUNN, R.M., BAIR, H.J., WOLF, F.G. and GOLDENBERG, D.M., Reduction of the renal uptake of monoclonal antibody fragments by amino acid infusion. J. nucl. Med., 37, 829-833 (1996).
4. BEHR, T.M. and GOLDENBERG, D.M., Improved prospects for cancer therapy with radiolabeled antibody fragments and peptides? J. nucl. Med., 37, 834-836 (1996).
5. BEHR, T.M., SHARKEY, R.M., JUWEID, M.E., BLUMENTHAL, R.D., DUNN, R.M., BAIR, H.J., GRIFFITHS, G.L., WOLF, F.G., BECKER, W.S. and GOLDENBERG, D.M., Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res., 55, 3825-3834 (1995).
6. BEHR, T.M., SHARKEY. R.M., JUWEID, M.E., DUNN, R.M., VAGG, R.C., YING, Z., ZHANG, C.H., SWAYNE, L.C., VARDI, Y., SIEGEL, J.A. and GOLDENBERG, D.M., Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J. nucl. Med., 38, 858-870 (1997a).
7. BEHR, T.M., SHARKEY, R.M., SGOUROS, G., BLUMENTHAL, R.D., DUNN, R.M., KOLBERT, K., GRIFFITHS, G.L., SIEGEL, J.A., BECKER, W.S. and GOLDENBERG, D.M., Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer, 80, 2591-2610 (1997b).
8. BEHR, T.M., WULST, E., RADETZKY, S., BLUMENTHAL, R.D., DUNN, R.M., GRATZ, S., RAVE-FRÄNK, M., SCHMIDBERGER, H., RAUE, F. and BECKER, W., Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res., 57, 5309-5319 (1997c).
9. BLUMENTHAL, R.D., KASHI, R., SHARKEY, R.M. and GOLDENBERG, D.M., Quantitative and qualitative effects of experimental radioimmuno-therapy on tumor vascular permeability. Int. J. Cancer, 61, 557-566 (1995a).
10. BLUMENTHAL, R.D., SHARKEY, R.M., FORMAN, D., WONG, G., HESS, J. and GOLDENBERG, D.M., Improved experimental cancer therapy by radioantibody dose intensification as a result of synceneic bone marrow transplantation. Exp. Hematol., 23, 1088-1097 (1995b).
11. BLUMENTHAL, R.D., SHARKEY, R.M. and GOLDENBERG, D.M., Overcoming dose-limiting, radioantibody-induced myelotoxicity. In D.M. Goldenberg (ed.), Cancer therapy with radiolabeled antibodies, pp. 295-314, CRC Press, Boca Raton, FL (1995c).
12. 131I-labeled monoclonal antibodies. Cancer Res., 52, 6036-6044 (1992).
13. 2 fragments. J. nucl. Med., 32, 1414-1421 (1991).
14. 2 as compared to intact antibodies in radioimmunotherapy of established human colon carcinoma grafted in nude mice. Recent Results Cancer Res., 141, 19-35 (1996).
15. BUCHSBAUM, D.J. AND ROBERSON, P.L., Experimental radioimmunotherapy: biological effectiveness and comparison with external beam radiation. Recent Results Cancer Res., 141, 9-18 (1996).
16. DALE, R.G., Dose-rate effects in targeted radiotherapy. Phys. Med. Biol., 41, 1871-1884 (1996).
17. DIVGI, C.R. and LARSON, S.M., Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin. nucl. Med., 19, 252-261 (1989).
18. DOWN, J.D., TARBELL, N.J., THAMES, H.D. and MAUCH, P.M., Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fractionation. Blood, 77, 661-669 (1991).
19. DUNCAN, J.R., BEHR, T.M. and DENARDO, S., Intracellular fate of radiometals. J. nucl. Med., 38, 829 (1997).
20. FITZGERALD, T.J., SANTUCCI, M.A., HARIGAYA, K., WODA, B., MCKENNA, M., SAKAKEENY, M.A., PIERCE, J.H., KASE, K., HOLLAND, C.A. and GREENBERGER, J.S., Radiosensitivity of permanent human bone marrow stromal cell lines: effects of dose rate. Int. J. Radiat. Oncol. Biol. Phys., 15, 1153-1159 (1988).
21. FOWLER, J.F., Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys., 18, 1261-1269 (1990).
22. 2, and Fab in tumors. Cancer Res., 49, 5656-5663 (1989).
23. FUJIMORI, K., COVELL, D.G., FLETCHER, J.E. and WEINSTEIN, J.N., A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier. J. nucl. Med., 31, 1191-1198 (1990).
24. GLASGOW, G.P., BEETHAM, K.L. and MILL, W.B., Dose rate effects on the survival of normal hematopoietic stem cells of BALB/c mice. Int. J. Radiat. Oncol. Biol. Phys., 9, 557-563 (1983).
25. GODDU, S.M., HOWELL, R.W. and RAO, D.V., Biologic dosimetry of bone marrow: implications for radionuclide therapy. Tumor Targeting, 2, 146 (1996) (abstract 23).
26. GOLDENBERG, D.M. (ed.), Cancer therapy with radiolabeled antibodies, CRC Press, Boca Raton, FL (1995).
27. GOLDENBERG, D.M., WITTE, S. and ELSTER, K., GW-39: a new human tumor serially transplantable in the golden hamster. Transplantation, 4, 760-764 (1966).
28. HANSEN, H.J., GOLDENBERG, D.M., NEWMAN, E.S., GREBENAU, R. and SHARKEY, R.M., Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer, 71, 3478-3485 (1993).
29. HENDRY, J.H. and LORD, B.I. (eds.), Radiation toxicology - Bone marrow and leukaemia. Taylor and Francis, London (1995).
30. HOWELL, R.W., GODDU, S.M. and RAO, D.V., Design and performance characteristics of an experimental cesium-137 irradiator to simulate internal radionuclide dose rate patterns. J. nucl. Med., 38, 727-731 (1997).
31. JAIN, R.K., Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res., 50, 814s-819s (1990).
32. JUWEID, M., NEUMANN, R., PAIK, C., PEREZ-BACETE, M.J., SATO, J., VAN OSDOL, W. and WEINSTEIN, J.N., Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res., 52, 5144-5153 (1992).
33. 2. J. nucl. Med., 37, 1504-1510 (1996).
34. KNOX, S.J., GORIS, M.L. and WESSELS, B.W., Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother. Oncol. 23, 111-117 (1992).
35. LANGMUIR, V.K., FOWLER, J.F., KNOX, S.J., WESSELS, B.W., SUTHERLAND, R.M. and WONG, J.Y.C., Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med. Phys., 20, 601-610 (1993).
36. 131l-labeled p97-specific Fab fragments in human melanoma as a basis of radiotherapy. J. din. Invest., 72, 2101-2114 (1983).
37. LARSON, S.M., CARRASQUILLO, J.A., MCGUFFIN, R.W., KROHN, K.A., FERENS, J.M., HILL, L.D., BEAUMIER, P.L., REYNOLDS, J.C., HELLSTRÖM, K.E. and HELLSTRÖM, I., Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology, 155, 487-492 (1985).
38. LING, C.C., SPIRO, I.J. and STICKLER, R., Dose-rate effect between 1 and 10 Gy/min in mammalian cell culture. Brit. J. Radiol., 57, 723-728 (1984).
39. MACKLIS, R.M., BERESFORD, B.A., PALAYOOR, S., SWEENEY, S. and HUMM, J.L., Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int. J. Radiat. Oncol. Biol. Phys. 27, 643-650 (1993).
40. MACKOVA, N. and PRASLICKA, M., Recovery of hematopoiesis in bone marrow of mice after continuous irradiation with dose rate 4.8 Gy/day. Neoplasma, 28, 79-86 (1981).
41. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet, 346, 336-340 (1995).
42. 131iodine-labeled antibody for a colon cancer model. Cancer Res., 55, 5811s-5816s (1995).
43. SGOUROS, G., Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. nucl. Meet., 34, 689-694 (1993).
44. SHADDUCK, R.K., WAHEED, A. and WING, E.J., Demonstration of a blood-bone marrow barrier to macrophage colony-stimulating factor. Blood. 73, 68-73 (1989).
45. SHARKEY, R.M., BLUMENTHAL. R.D., BEHR, T.M., WONG, G.Y., HAYWOOD, L., FORMAN, D., GRIFFITHS, G.L. and GOLDENBERG, D.M., Selection of radioimmunoconjugates tor the therapy of well-established or micrometastatic colon carcinoma. Int. J. Cancer, 72, 477-485 (1997).
46. SHARKEY, R.M., MOTTA-HENNESSY, C., PAWLYK, D., SIEGEL, J.A. and GOLDENBERG, D.M., Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res., 50, 2330-2336 (1990).
47. SHIH, L.B., THORPE, S.R., GRIFFITHS, G.L., DIRIL, H., ONG, G.L., HANSEN, H.J., GOLDENBERG, D.M. and MATTES, M.J., The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J. nucl. Med., 35, 899-908 (1994).
48. SIEGEL, J.A. and STABIN, M.G., Absorbed fractions for electrons and beta particles in spheres of various sizes. J. nucl. Med., 35, 152-156 (1994).
49. 131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma. Int. J. Radiat. Oncol. Biol. Phys., 21, 1601-1605 (1991).
50. TARBELL, N.J., AMATO, D.A., DOWN, J.D., MAUCH, P. and HELLMAN, S., Fractionation and dose rate effects in mice: a model for bone marrow transplantation in man. Int. J. Radiat. Oncol. Biol. Phys., 13, 1065-1069 (1987).
51. VAN Os, R., THAMES, H.D., KONINGS, A.W. and DOWN, J.D., Radiation dose-fractionation and dose-rate relationships for long-term repopulating hemopoietic stemm cells in a murine bone marrow transplant model. Radiat. Res., 136, 118-125 (1993).
52. YAMAMOTO, O., YOKORO, K., SEYAMA, T., KINOMURA, A. and NOMURA, T., HTO oral administration in mice. I. Threshold dose rate for haematopoietic death. Int. J. Radiat. Biol., 57, 543-549 (1990).